TTI.V Thiogenesis Therapeutics Corp.

Healthcare Biotechnology TSX Venture Exchange
0.6400 CAD
Close of Nov 7, 2026
0.4400 0.7400
Market cap
CAD 44.8M
P/E
-
P/B
6.56x
ROE
-71.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is TTI.V undervalued?

Graham number

The Graham number of Thiogenesis Therapeutics Corp. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Thiogenesis Therapeutics Corp. fundamental analysis

No fundamental analysis for Thiogenesis Therapeutics Corp. yet.

Thiogenesis Therapeutics Corp. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Thiogenesis Therapeutics Corp.

Thiogenesis Therapeutics, Corp., a clinical-stage biopharmaceutical company, develops thiol-based therapeutic compounds to treat unmet pediatric medical needs. The company lead product candidate is TTI-0102, a prodrugs that consists of cysteamine for use in the treatment of mitochondrial encephalopathy lactic acidosis and stroke-like episodes, leigh syndrome, pediatric metabolic dysfunction-associated steatohepatitis, and nephropathic cystinosis. The company is headquartered…

Full company profile